Current Position: Home>>Cancer Research Antibodies
At present, more than 30 antibodies or antibody derivatives have been approved for cancer treatment by FDA, and hundreds of antibodies are in the process of clinical trials. Antibodies have become a new choice for cancer treatment. Anti-cancer antibodies can target a wide range of antigens, including soluble proteins, cancer cell surface antigens and effector cell receptors.
The versatility of antibodies enables antibodies to take a variety of mechanisms, including direct blocking of growth factors, regulation of the immune system, and interruption or induction of signal transduction pathways. In addition, antibodies are increasingly used as carriers to improve the specificity of specific chemotherapeutic drugs.
view more
view more
view more
view more
view more
view more
view more
view more
view more
view more
view more
view more
PTEN is a widespread and closely related tumor suppressor gene, which has abnormal expression in glioblastoma, breast cancer, lung cancer, bladder cancer, thyroid cancer, head and neck squamous cell carcinoma, melanoma, lymphoma and other tumors.
POSTN is an extracellular matrix periosteal protein, which can support the growth of transferase in the formed microenvironment by enhancing Wnt signaling in tumor cells. In adults, it is expressed in specific organs such as breast, bone, skin and intestine.
Alpha fetoprotein is closely related to the occurrence and development of liver cancer and many kinds of tumors. It shows high concentration in many kinds of tumors and can be used as a positive detection index for many kinds of tumors.
There are high or abnormal expression of EGFR in many solid tumors. EGFR is related to tumor cell proliferation, angiogenesis, tumor invasion, metastasis and inhibition of apoptosis.
CK18 is a normal cytoskeleton component of hepatocytes and a standard of tumor markers. CK18 levels were increased in patients with benign liver disease, especially those with significant cytolysis.
IL-6R can specifically combine with IL-6 to block the related diseases caused by IL-6 and reduce the severity of asthma, multiple sclerosis, chronic rheumatoid arthritis and other diseases.